TD Cowen Increases TransMedics Group (NASDAQ:TMDX) Price Target to $130.00

TransMedics Group (NASDAQ:TMDX) had its price target increased by TD Cowen from $100.00 to $130.00 in a report published on Wednesday, Benzinga reports. TD Cowen currently has a buy rating on the stock.

A number of other brokerages have also weighed in on TMDX. Oppenheimer upped their price target on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an outperform rating in a research note on Wednesday. Canaccord Genuity Group boosted their price objective on TransMedics Group from $102.00 to $117.00 and gave the stock a buy rating in a research note on Wednesday. Piper Sandler reaffirmed an overweight rating and set a $120.00 target price (up previously from $95.00) on shares of TransMedics Group in a research note on Wednesday. JPMorgan Chase & Co. boosted their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an overweight rating in a research report on Wednesday. Finally, Morgan Stanley raised their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and a consensus target price of $119.00.

TransMedics Group Stock Performance

Shares of NASDAQ TMDX opened at $127.99 on Wednesday. TransMedics Group has a 12-month low of $36.42 and a 12-month high of $129.66. The company has a market cap of $4.19 billion, a PE ratio of -376.44 and a beta of 1.87. The stock has a 50 day simple moving average of $85.54 and a 200-day simple moving average of $76.85. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.40. TransMedics Group had a positive return on equity of 8.29% and a negative net margin of 3.43%. The company had revenue of $96.90 million during the quarter, compared to analysts’ expectations of $83.78 million. During the same quarter in the prior year, the business posted ($0.08) earnings per share. The company’s revenue for the quarter was up 132.9% compared to the same quarter last year. On average, equities research analysts forecast that TransMedics Group will post -0.14 EPS for the current year.

Insider Transactions at TransMedics Group

In related news, CEO Waleed H. Hassanein sold 56,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total value of $6,475,280.00. Following the completion of the sale, the chief executive officer now owns 74,087 shares in the company, valued at approximately $8,566,679.81. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other TransMedics Group news, insider Tamer I. Khayal sold 736 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the sale, the insider now directly owns 14,375 shares in the company, valued at approximately $1,295,043.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Waleed H. Hassanein sold 56,000 shares of TransMedics Group stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $115.63, for a total value of $6,475,280.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $8,566,679.81. The disclosure for this sale can be found here. Insiders have sold a total of 236,378 shares of company stock valued at $23,633,449 over the last ninety days. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Several institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new position in shares of TransMedics Group during the 1st quarter valued at $30,000. Fidelis Capital Partners LLC acquired a new stake in TransMedics Group during the first quarter valued at $35,000. Cutler Group LLC CA grew its stake in TransMedics Group by 600.0% in the third quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock valued at $38,000 after purchasing an additional 600 shares in the last quarter. First Horizon Advisors Inc. increased its position in TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock worth $83,000 after purchasing an additional 222 shares during the last quarter. Finally, RiverPark Advisors LLC purchased a new stake in shares of TransMedics Group during the 3rd quarter worth about $60,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.